IN THE CLAIMS:

1. A treated core comprising:

a core substrate; and

apixaban and a carrier on the core substrate.,

2. Thewherein the treated core of claim 1, comprises from 0.001% w/w to 0.20% w/w apixaban,

wherein the apixaban and the carrier are in a layer formed on a surface of the core substrate.,

3. The treated core of claim 2, wherein the apixaban and the carrier are applied to the surface of the core substrate by a spray-layered dispersion process carried out with a concentration of apixaban in a solvent below the solubility limit.

42. The treated core of any one of claimsclaim 1-3, wherein the core substrate is a sugar bead or sphere, or a microcrystalline cellulose, lactose, or mannitol particle.

3.

5. The treated core of any one of claims claim 1-4, wherein the core substrate is a sugar bead or sphere.

6. The treated core of any one of claims 1-5, wherein the sugar bead or sphere comprises sugar syrup, corn starch, and/or sucrose.

7. The treated core of any one of claims 1-6, wherein the carrier is hydroxypropylcellulose and/or hypromellose.

8. The treated core of any one of claims 1-72, having a core size from about 150 microns to about 355 microns.

94. A formulation comprising at least one said treated core of any one of claims 1-83.

5.

10. The formulation of claim 94, which:

(a) has an apixaban content from about 0.09% w/w to about 0.11% w/w.;

~~11. The formulation of claim 9 or 10, which~~ (b) has a carrier content from about 9% w/w to about 11% w/w~~.~~;

~~12. The formulation of any one of claims 9-11, which~~ (c) has a core substrate content from about 89% w/w to about 91% w/w~~.~~; or

~~13. The formulation of any one of claims 9-12, which~~ (d) has an apixaban content of about 0.1% w/w.

~~14~~6. The formulation of ~~any one of claims 9-13~~claim 4 or 5, wherein the at least one said treated core is in a capsule.

~~15~~7. The formulation of any one of claims ~~9-13~~4-6, wherein the capsule is a gelatin capsule or an HPMC capsule~~.~~

~~16. The formulation of claim 14 or 15, wherein the capsule is~~ or a sprinkle capsule.

~~17~~8. The formulation of ~~any one of claims 14-16~~claim 6 or 7, wherein the capsule comprises about 0.1 mg apixaban.

~~18~~9. A ~~method~~treated core of any one of claims 1-3 for use in treating a thromboembolic disorder in a subject in need thereof comprising:
dispersing and/or dissolving at least one said treated core ~~of any one of claims 1-8~~ in a liquid carrier and
administering the liquid carrier to the subject .

~~19~~10. The ~~method of~~treated core for use according to claim ~~18~~9, wherein the liquid carrier is a food or beverage.

~~20~~11. The ~~method of~~treated core for use according to claim ~~18~~9 or ~~19~~10, wherein the subject is a neonate.

2112. The treated core of any one of claims 1-83 or the formulation of any one of claims 9-1748 for use in a treatment of a thromboembolic disorder, or for use in a preparation of a medicament for the treatment of a thromboembolic disorder.

22. A13. The formulation comprising:

at least one treated core comprising:

a core substrate; and

a carrier on the core substrate,

of claim 4 or 5, wherein the formulation comprises about 0.1 mg to about 0.4 mg of apixaban.

2314. The formulation of claim 22, which has a carrier content from about 9% w/w to about 11% w/w.

24. The formulation of claims 22 or 23, which has a core substrate content from about 89% w/w to about 91% w/w.

25. The formulation of any one of claims 22-24, which has an apixaban content of about 0.1% w/w to about 0.4% w/w.

26. The formulation of any one of claims 22-25, wherein the formulation comprises about 0.1 mg of apixaban.

27. The formulation of any one of claims 22-2513, wherein the formulation comprises about 0.2 mg of apixaban.

2815. The formulation of any one of claims 22-25claim 13, wherein the formulation comprises about 0.3 mg of apixaban.

2916. The formulation of any one of claims 22-25claim 13, wherein the formulation comprises about 0.4 mg of apixaban.

3017. The formulation of any one of claims 22-2913-16, wherein the at least one treated core is in a capsule.

~~31~~18. The formulation of claim ~~30~~17, wherein the capsule is a sprinkle capsule.